Category Cannabis

From August’s DEA closing briefs to September’s developments: the U.S. medical framework survives a stay request, Congress delays part of the hemp restrictions, Germany raises new questions and Aurora battles Curaleaf. Meanwhile, company accounts are telling increasingly different stories.

Every party in the DEA rescheduling case filed on August 17. The Government asked for Schedule III; all six other filings asked that marijuana stay in Schedule I. What the 274 pages say, what the sector reported, and which dates are real.

The July 15 testimony is over. There is no verdict, no vote and no broad Schedule III final rule yet. The hearing nevertheless clarified which parts of the government’s case survived, where the opposition created real legal risk and what investors should watch next.

Week two of the DEA marijuana rescheduling hearing: Dr. Kenneth Finn's testimony, the Tennessee Bureau of Investigation, the July 13-15 final stretch, and the non-binding path to a Schedule III Final Rule - and what it means for $MSOS, $TLRY, $CGC and $ACB.

The July cannabis trade is no longer about a simple “rescheduling soon” headline. It is about the administrative record being built inside the DEA hearing room: medical use, abuse potential, dependence profile, public-safety arguments, product-standardization attacks, impaired-driving concerns and the litigation path that may follow any final Schedule III decision.

The market did not get a final ruling today. What it got is the start of a federal process that could decide whether the cannabis trade remains a narrow medical-only tax story or becomes a broader sector repricing catalyst.

The cannabis trade is no longer the same speculative legalization trade that dominated the previous cycle. Cronos, Canopy Growth and Tilray now represent three different Nasdaq-listed cannabis reset stories: one balance-sheet name, one turnaround catalyst name, and one diversified global medical and consumer platform.

The cannabis trade is no longer just about reform headlines. Cronos, Organigram and SNDL have now reported fresh numbers, and the message is clear: the sector may have a policy catalyst, but operating quality, balance-sheet strength, international exposure and margin discipline are starting to separate the stronger stories from the more fragile ones.

The cannabis sector is back on trader radar because Washington finally gave the market something concrete to trade around. The Department of Justice placed FDA-approved marijuana products and qualifying state-licensed medical marijuana products into Schedule III, while also pointing to a new administrative hearing beginning June 29, 2026, on the broader marijuana rescheduling process.

Akanda Corp. is one of the clearest examples of how a powerful sector catalyst can ignite an extremely small, structurally fragile, low-float equity without necessarily changing the underlying business. The April 2026 rally was real as a market event, but it should not be misread as fundamental confirmation. The stock moved because federal cannabis reform returned to the front page, because Akanda had just completed a 1-for-4.5 reverse stock split, and because the post-split share structure made the name unusually sensitive to retail momentum, scanner activity and possible short-covering dynamics.

Three separate state-level moves — Maryland’s public-health labeling discussion, Massachusetts’ near-term governance and licensing overhaul, and California’s pesticide testing rulemaking — may not look like classic headline catalysts at first glance. But for cannabis operators, labs, manufacturers, packaging vendors, distributors, and investors watching margin pressure, market access, and compliance risk, these are exactly the types of regulatory shifts that can quietly reshape the sector.